Skip to main content

Significant investments

Typically, building a strategic position begins with investments in private companies with development potential and expands at follow-on financing rounds as well as potentially IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 March 2018

CHF
87
million
Cathay Industrial Biotech
Vectura Group
CHF
65
million
CHF
57
million
ARMO Biosciences
Argenx
CHF
38
million
CHF
33
million
Pacira Pharmaceuticals
TandemLife
CHF
31
million
CHF
31
million
Harmony Biosciences